| Year |
Citation |
Score |
| 2010 |
Xi H, Katschke KJ, Helmy KY, Wark PA, Kljavin N, Clark H, Eastham-Anderson J, Shek T, Roose-Girma M, Ghilardi N, van Lookeren Campagne M. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. The Journal of Experimental Medicine. 207: 7-16. PMID 20038601 DOI: 10.1084/Jem.20091508 |
0.346 |
|
| 2009 |
Li B, Xi H, Diehl L, Lee WP, Sturgeon L, Chinn J, Deforge L, Kelley RF, Wiesmann C, van Lookeren Campagne M, Sidhu SS. Improving therapeutic efficacy of a complement receptor by structure-based affinity maturation. The Journal of Biological Chemistry. 284: 35605-11. PMID 19833734 DOI: 10.1074/Jbc.M109.035170 |
0.333 |
|
| 2007 |
Katschke KJ, Helmy KY, Steffek M, Xi H, Yin J, Lee WP, Gribling P, Barck KH, Carano RA, Taylor RE, Rangell L, Diehl L, Hass PE, Wiesmann C, van Lookeren Campagne M. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. The Journal of Experimental Medicine. 204: 1319-25. PMID 17548523 DOI: 10.1084/Jem.20070432 |
0.309 |
|
| 2006 |
Xi H, Schwartz R, Engel I, Murre C, Kersh GJ. Interplay between RORgammat, Egr3, and E proteins controls proliferation in response to pre-TCR signals. Immunity. 24: 813-26. PMID 16782036 DOI: 10.1016/J.Immuni.2006.03.023 |
0.458 |
|
| 2004 |
Xi H, Kersh GJ. Sustained early growth response gene 3 expression inhibits the survival of CD4/CD8 double-positive thymocytes. Journal of Immunology (Baltimore, Md. : 1950). 173: 340-8. PMID 15210792 DOI: 10.4049/Jimmunol.173.1.340 |
0.429 |
|
| 2004 |
Xi H, Kersh GJ. Early growth response gene 3 regulates thymocyte proliferation during the transition from CD4-CD8- to CD4+CD8+. Journal of Immunology (Baltimore, Md. : 1950). 172: 964-71. PMID 14707069 DOI: 10.4049/Jimmunol.172.2.964 |
0.375 |
|
| 2003 |
Bettini M, Xi H, Kersh GJ. T cell stimulation in the absence of exogenous antigen: a T cell signal is induced by both MHC-dependent and -independent mechanisms. European Journal of Immunology. 33: 3109-16. PMID 14579279 DOI: 10.1002/Eji.200324067 |
0.391 |
|
| 2003 |
Xi H, Kersh GJ. Induction of the early growth response gene 1 promoter by TCR agonists and partial agonists: ligand potency is related to sustained phosphorylation of extracellular signal-related kinase substrates. Journal of Immunology (Baltimore, Md. : 1950). 170: 315-24. PMID 12496415 DOI: 10.4049/Jimmunol.170.1.315 |
0.4 |
|
| 2003 |
Xi H, Blanck G. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1. Molecular Immunology. 39: 677-84. PMID 12493643 DOI: 10.1016/S0161-5890(02)00214-6 |
0.69 |
|
| 2002 |
Bettini M, Xi H, Milbrandt J, Kersh GJ. Thymocyte development in early growth response gene 1-deficient mice. Journal of Immunology (Baltimore, Md. : 1950). 169: 1713-20. PMID 12165491 DOI: 10.4049/Jimmunol.169.4.1713 |
0.401 |
|
| 2001 |
Xi H, Goodwin B, Shepherd AT, Blanck G. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene. 20: 4219-27. PMID 11464288 DOI: 10.1038/Sj.Onc.1204556 |
0.713 |
|
| 2001 |
Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 12: 327-35. PMID 11432807 |
0.651 |
|
| 2000 |
Xi H, Blanck G. Interferon regulatory factor-2 point mutations in human pancreatic tumors. International Journal of Cancer. 87: 803-8. PMID 10956389 DOI: 10.1002/1097-0215(20000915)87:6<803::Aid-Ijc7>3.0.Co;2-E |
0.663 |
|
| 1999 |
Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL, Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 18: 5889-903. PMID 10557076 DOI: 10.1038/Sj.Onc.1202969 |
0.648 |
|
| Show low-probability matches. |